Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on December 11, 2023. The report details the results of the reconvened 2023 Annual Meeting of Stockholders held on the same date. The primary matter addressed was Proposal 3, concerning the Company's reincorporation from the State of Delaware to the State of Nevada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved the Reincorporation proposal. As of the record date of October 12, 2023, there were 3,109,497 shares of common stock outstanding. A quorum was present at the reconvened meeting. The final vote tally was as follows:
| Vote Category | Number of Shares |
|---|---|
| For | 1,589,197 |
| Against | 43,858 |
| Abstain | 10,276 |
| Broker Non-Vote | 40,875 |
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risks associated with the reincorporation process beyond the procedural approval. No unusual items or contingencies were disclosed in this specific report.
Key Facts for Investor Verification
- Stockholders have approved the reincorporation of Silo Pharma, Inc. from Delaware to Nevada.
- The vote passed with approximately 97% of the votes cast in favor (1,589,197 For vs. 43,858 Against).
- The Company is an emerging growth company, though it has not elected to use the extended transition period for new accounting standards.
- Investors should verify the effective date of the reincorporation and any subsequent changes to the Company's charter or bylaws.